First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer ...

Johnson & Johnson reported a 73% PSA response rate in a 15-patient Phase 1 trial of its dual bispecific antibody combo for ...

A comprehensive review published in Genes and Environment examines the complex relationship between tobacco smoking and ...

Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to ...

Stage 4 prostate cancer is advanced and has spread beyond the prostate. Hormone therapy is often used to treat stage 4 prostate cancer by reducing testosterone. Chemotherapy can help prolong life and ...

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at ...

A narrative review in the African Journal of Urology outlines adaptive strategies for managing metastatic prostate cancer in ...

Scientists hope to double survival rates for patients with the deadliest blood cancers by adopting a trial approach that has ...

An analysis of tissue samples from patients with prostate cancer showed that the loss of the nuclear receptor coactivator 6 (NCOA6) protein was associated with more aggressive disease and high ...

Bayer’s Nubeqa is already well established in prostate cancer, but DASL-HiCaP data broadens potential patient populations.

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted ...

Darolutamide improved metastasis-free survival alongside hormone therapy and radiotherapy in very high-risk prostate cancer.